EE714 A De Novo Cost-Effectiveness Model to Evaluate the Real-World Value of Pegcetacoplan in the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration in the United States
Abstract
Authors
A.K. Cummings Joyner M. Crowell S.P. Sarda M. Intorcia D. Jones W. Stevens